Companies › Perspective Therapeutics
2 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [212Pb]VMT-α-NET | – | Phase 1 | Recurrent Melanoma (Skin); Pancreatic Ductal Adenocarcinoma; Neuroendocrine Tumors Unresectable | Dec 2027 |
| [203Pb]Pb-PSV359 FAP-targeting radiopharmaceutical with lead-203 for imaging | FAP | Phase 1 | Pancreatic Ductal Adenocarcinoma | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05655312 | [212Pb]VMT-α-NET | Phase 1 | Recurrent Melanoma (Skin) | Oncology | Dec 2027 |
| NCT06710756 | [212Pb]VMT-α-NET | Phase 1 | Pancreatic Ductal Adenocarcinoma | Oncology | Jan 2028 |
| NCT06710756 | [203Pb]Pb-PSV359 | Phase 1 | Pancreatic Ductal Adenocarcinoma | Oncology | Jan 2028 |
| NCT05636618 | [212Pb]VMT-α-NET | Phase 1 | Neuroendocrine Tumors Unresectable | Oncology | Nov 2029 |
Cash and short-term investments of $202m on 2026-09-30; operating cash outflow about $112m a year; runway about 22 months at that burn, to Jul 2028
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.